Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Jul 18, 2018 (8 years ago)

Valsartan

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.

Cause type: Nitrosamine impurity

Trace nitrosamine impurities such as NDMA, NDEA or NMBA found above the acceptable daily limit. Nitrosamines are probable human carcinogens that can form during manufacturing or storage. This is the cause behind the large valsartan, losartan and ranitidine (Zantac) recalls. All nitrosamine impurity recalls.

What was recalled

Valsartan, 160 mg, 30 tablets per bottle, Rx Only, Repackaged By: Northwind Pharmaceuticals, Indianapolis, IN 46256. NDC: 51655-460-52

Affected NDC 51655-0460-52

Compare with the code on your package — it is the most precise check available.

Drug: Valsartan Category: Blood Pressure Medication

Recalling firm
Northwind Pharmaceuticals LLC
Origin
IN, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-1095-2018 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Valsartan recalls

See all
Class II · Moderate risk

Diovan (valsartan)

Failed Dissolution Specifications

Ongoing Dissolution failure Novartis Pharmaceuticals Corporation NDC 0078-0359-34 D-0746-2026
Class II · Moderate risk

Valsartan Tablets 320 mg USP

CGMP Deviations; Detection of a trace amount of unexpected impurity N- nitrosodiethylamine (NDEA) found in finished products

Ongoing Nitrosamine impurity Rising Pharmaceuticals, Inc. NDC 52343-125-90 D-1055-2019
Class II · Moderate risk

Valsartan Tablets 160 mg USP

CGMP Deviations; Detection of a trace amount of unexpected impurity N- nitrosodiethylamine (NDEA) found in finished products

Ongoing Nitrosamine impurity Rising Pharmaceuticals, Inc. NDC 52343-124-90 D-1054-2019
Class II · Moderate risk

Valsartan Tablets 80 mg USP

CGMP Deviations; Detection of a trace amount of unexpected impurity N- nitrosodiethylamine (NDEA) found in finished products

Ongoing Nitrosamine impurity Rising Pharmaceuticals, Inc. NDC 52343-123-90 D-1053-2019

Other recalls by Northwind Pharmaceuticals LLC

All 2018 recalls
Class II · Moderate risk

Sulfamethoxazole and Trimethoprim Tablets

Presence of a Foreign Substance: A specific lot of auxiliary polyester coil, used in product packaging by manufacturer (Amneal Pharmaceuticals LLC) was detected with presence of a micro-organism. No micro-organism was detected on any tablets.

Ongoing Particulate / foreign matter Northwind Pharmaceuticals LLC NDC 51655-307-87 D-0654-2025
Class II · Moderate risk

Tadalafil Tablets

CGMP Deviations

Ongoing cGMP deviation Northwind Pharmaceuticals LLC NDC 51655-487-52 D-0554-2023
Class II · Moderate risk

Tadalafil Tablets

CGMP Deviations

Ongoing cGMP deviation Northwind Pharmaceuticals LLC NDC 51655-473-87 D-0553-2023